NCT Number: NCT00273481
Cosopt Versus Xalacom
To compare the intraocular pressure efficacy and safety of the DTFC given twice daily versus the LTFC given once every morning following a run-in period with timolol maleate given twice daily.
Looking for future studies?
Notify MeKey information
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Primary location
Lawson Health Research Insitute, London, Ontario, Canada
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- adults with primary open-angle or pigment-dispersion glaucoma, or ocular hypertension
- at baseline the intraocular pressure should be 20 to 32 mm Hg inclusive at 08:00 measurement (Visit 2) after dosing with timolol the evening before
- the intraocular pressure should be 32 mm Hg or less at all the time points in both eyes at Visit 2
- visual acuity should be 6/60 or better in the study eye(s)
Exclusion criteria
- any anticipated change in systemic hypotensive therapy during the trial
- use of any corticosteroids by any route for more than two weeks during the study
- contraindications to study medicines
Treatment and study plan
latanoprost 0.005%/timolol maleate 0.5% fixed combination
Drugtimolol maleate 0.5%
DrugPlacebo
DrugSponsors and collaborators
Lead sponsor
Pharmaceutical Research Network
Other
Registry information
Important dates
- Study start
- 2005
- Study completion
- 2007
- First posted
- Jan 9, 2006
- Registry last updated
- Nov 19, 2008
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
NCT03891446
Eye Diseases, Glaucoma
Dothan, Alabama, United States
View Trial DetailsEvaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
NCT03850782
Eye Diseases, Glaucoma
Sun City, Arizona, United States
View Trial Details18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)
NCT04647214
Eye Diseases, Glaucoma
Culver City, California, United States
View Trial DetailsNebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension
NCT04910100
Eye Diseases, Glaucoma
Newport Beach, California, United States
View Trial Details